By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today announced an agreement with investment bank MLV & Co. for the potential sale of an aggregate of $30 million of its common stock.

The sale of Complete Genomics' stock would be made on the Nasdaq Global Market under the Mountain View, Calif.-based firm's currently effective Form S-3 at market prices. Shares also may be sold through MLV at negotiated prices or at prices related to the prevailing market price, Complete Genomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.